论文部分内容阅读
目的探讨瑞舒伐他汀在改善急性冠状动脉综合征合并心律失常患者炎性因子中的作用。方法选取2014年1月至2015年6月沈阳市红十字会医院收治的急性冠状动脉综合征合并心律失常患者90例为研究对象,按随机数字表法分为对照组和观察组,每组45例。对照组患者采用洛伐他汀治疗,观察组患者采用瑞舒伐他汀治疗,比较两组患者治疗前后炎性因子的改善情况。结果两组患者治疗前超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-18(IL-18)、Bcl-2及C-myc蛋白表达水平比较,差异均无统计学意义(均P>0.05);治疗后两组患者炎性因子均明显改善,且观察组患者炎性因子改善程度明显优于对照组,差异有统计学意义(P<0.05);且治疗后观察组患者Bcl-2及C-myc蛋白表达水平均明显优于对照组,差异均有统计学意义(均P<0.05)。结论给予急性冠状动脉综合征合并心律失常患者瑞舒伐他汀治疗可有效改善患者炎性因子水平,且可减少患者心肌细胞凋亡,临床价值显著。
Objective To investigate the effect of rosuvastatin on inflammatory factors in patients with acute coronary syndrome complicated with arrhythmia. Methods From January 2014 to June 2015, 90 patients with acute coronary syndrome and arrhythmia admitted to Shenyang Red Cross Hospital were enrolled and divided into control group and observation group according to random number table example. The patients in the control group were treated with lovastatin, and the patients in the observation group were treated with rosuvastatin. The improvement of inflammatory factors in both groups before and after treatment was compared. Results The levels of hs-CRP, TNF-α, IL-18, Bcl-2 and C-myc before treatment in both groups were significantly higher than those before treatment (All P> 0.05). The inflammatory factors in both groups were significantly improved after treatment, and the improvement of inflammatory factors in the observation group was better than that in the control group, the difference was statistically significant (P <0.05 ). After treatment, the expressions of Bcl-2 and C-myc in the observation group were significantly better than those in the control group (all P <0.05). Conclusions Treatment with rosuvastatin in patients with acute coronary syndrome and arrhythmia can effectively improve the level of inflammatory cytokines and reduce the apoptosis of myocardial cells in patients with acute coronary syndrome. The clinical value is significant.